CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Eom Pharmaceutical Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Eom Pharmaceutical Holdings Inc
30721 Russell Ranch Road, Suite 140
Phone: (818) 264-2300p:818 264-2300 WESTLAKE VILLAGE, CA  91362  United States Ticker: IMUCIMUC
This company ceased filing statements with the SEC on 11/6/2018.
Business Summary
EOM Pharmaceutical Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing novel drugs for patients suffering from debilitating and deadly diseases, including infectious diseases; autoimmune diseases including rheumatoid arthritis; and cachexia associated with acquired immune deficiency syndrome (AIDS) and cancer. It has two pipeline assets in their portfolio: EOM613 and EOM147. EOM613 is an investigational immunomodulator. EOM613 is a peptide-nucleic acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokine effects. EOM613 helps to suppress or stimulate monocytes and macrophages depending on the activation state and environment of those key immune cells resulting in either further activation or suppression. EOM 147 is an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of retinal diseases. EOM147 affects multiple angiogenic growth factors such as VEGF, PdGF, and bFGF.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202212/31/2021YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Operating Officer EliGoldberger 32 12/1/2021 12/1/2021
President, Chief Executive Officer, Director Irach B.Taraporewala 66 12/1/2021 12/1/2021
Chief Financial Officer, Treasurer Wayne I.Danson 68 12/1/2021 12/1/2021
4 additional Officers and Directors records available in full report.

Business Names
Business Name
EOM Pharmaceuticals, Inc.
ImmunoCellular Therapeutics Ltd(NDA)
ImmunoCellular Therapeutics Ltd.
7 additional Business Names available in full report.

General Information
Number of Employees: 3 (As of 8/10/2022)
Outstanding Shares: 113,270,751 (As of 3/31/2022)
Shareholders: 41
Stock Exchange: OTC
Federal Tax Id: 931301885
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, October 29, 2024